Current financial headlines

Sharemaestro Newsreel

Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.

Showing
937–972
Headlines
1784
Sources here
23
Companies here
13
Current section United States Drug Manufacturers - General news

Chronological news

Earlier headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Stock Titan Earnings Main company 🇺🇸 United States

Amgen Sets Sept. 11 Payment Date for $2.52 Dividend

Amgen (NASDAQ: AMGN) has declared a cash dividend of $2.52 per share for the third quarter of 2026. This dividend is scheduled to be paid on September 11, 2026, to stockholders who are on record as of the close of business on August 21, …

AMGN main company
Sharemaestro market context Trend signal active 52 weeks +44.4% AMGN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
OpenSecrets Market update Main company 🇺🇸 United States

Novartis AG Lobbyists, 2023

This article from OpenSecrets.org details the lobbying activities of Novartis AG in 2023. It lists 73 lobbyists hired by Novartis, with 56 (76.7%) of them having previous federal government experience, indicating a significant "revolving door" phenomenon. The report also names the firms that employed …

NVS main company
Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2% NVS stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GuruFocus Analyst action Main company 🇺🇸 United States

BIIB Maintains Rating by Morgan Stanley -- Price Target Raised to $231

Morgan Stanley has reiterated its "Equal-Weight" rating for Biogen (BIIB) and increased its price target from $222.00 to $231.00. Despite this positive adjustment, GuruFocus's GF Value™ indicates that Biogen is currently 7.2% overvalued. The company's GF Score™ of 68/100 points to strong profitability and …

BIIB main company
Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3% BIIB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Seeking Alpha Earnings Main company 🇺🇸 United States

Bristol-Myers, Merck win FDA review for Reblozyl label expansion

The FDA has accepted Bristol-Myers Squibb's marketing application for an expanded U.S. label for its anemia therapy, Reblozyl. This drug was developed in partnership with Merck. The announcement was made during Bristol-Myers Squibb's Q2 2026 financial report.

MRK main company BMY main company
Sharemaestro market context Trend signal active 52 weeks +60.7% MRK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Fierce Pharma Earnings Provider-linked mention 🇺🇸 United States

New CEO Garijo sketches out vision to reverse Sanofi's fortunes as Q2 delivers impressive sales beat

Sanofi's new CEO, Belén Garijo, outlined her vision to revitalize the company during her inaugural earnings call, following a strong Q2 performance with sales exceeding forecasts by 8%. While the immunology drug Dupixent significantly contributed to this success, Garijo emphasized the need to diversify …

SNY mentioned
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1% SNY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Fierce Biotech Deals and strategy Main company 🇺🇸 United States

Sanofi CEO ‘looking deeply’ at pipeline as clearout continues

Sanofi's new CEO, Belén Garijo, is undertaking a rigorous assessment of the company's late-stage pipeline, leading to the discontinuation of several previously touted drug candidates. Her strategy focuses on investing where science is strongest and unmet medical needs are greatest, while also considering acquisitions …

SNY main company
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1% SNY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Pharmaceutical Executive Deals and strategy Main company 🇺🇸 United States

M&A Roundup: Johnson & Johnson Collaborates with Sail Biomedicines, Processa Pharmaceuticals Acquires Vidya Therapeutics, Relation Collaborates with GSK

This M&A Roundup highlights three significant collaborations and acquisitions in the biopharmaceutical sector. Johnson & Johnson is moving to acquire Sail Biomedicines, an in vivo CAR-T therapy developer, with an initial investment of $785 million and an option to acquire for $2.58 billion. Processa …

JNJ main company
Sharemaestro market context Trend signal active 52 weeks +48.8% JNJ stored weekly price path from 22 Aug 2025 to 14 Aug 2026
BioSpace Earnings Main company 🇺🇸 United States

Merck Announces Fourth-Quarter 2026 Dividend

Merck (NYSE: MRK) has declared a quarterly dividend of $0.85 per share for the fourth quarter of 2026. The payment is scheduled for October 7, 2026, for shareholders of record as of September 15, 2026. The announcement was made by the company's Board of …

MRK main company
Sharemaestro market context Trend signal active 52 weeks +60.7% MRK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketWatch Market update Main company 🇺🇸 United States

Gilead Sciences Inc. stock outperforms competitors despite losses on the day

Gilead Sciences Inc. (GILD) saw its stock shed 1.09% to $131.28 on Thursday, marking its second consecutive day of losses. This occurred despite a generally favorable trading session for the broader market, with the S&P 500 Index and Dow Jones Industrial Average both experiencing …

GILD main company
Sharemaestro market context Price above Trend Line 52 weeks +23.7% GILD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketWatch Market update Main company 🇺🇸 United States

AbbVie Inc. stock outperforms competitors despite losses on the day

AbbVie Inc. (ABBV) shares declined by 2.24% to $257.41, breaking a two-day winning streak, despite an overall positive trading day for the broader market. Both the S&P 500 Index and the Dow Jones Industrial Average saw gains on Thursday. This report highlights AbbVie's performance …

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6% ABBV stored weekly price path from 22 Aug 2025 to 14 Aug 2026
BioSpectrum India Deals and strategy Main company 🇺🇸 United States

ChrysCapital acquires 70.68% stake in Novartis India

Private equity firm ChrysCapital has acquired a controlling 70.68% stake in Novartis India Limited (NIL), a BSE-listed company previously held by Novartis AG. This acquisition marks ChrysCapital's first majority-controlled investment in the Indian pharmaceutical sector, aiming to transform Novartis India into a leading branded-generics …

NVS main company
Sharemaestro market context Trend signal active 52 weeks +22.5% · Next-week setup positive 61.2% NVS stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Benzinga Earnings Main company 🇺🇸 United States

Pfizer Prepares Global Regulatory Litfulo Filings Following Skin Pigment Improvements In Late-Stage Trial

Pfizer has announced positive topline data from two Phase 3 clinical trials for LITFULO, its once-daily treatment for nonsegmental vitiligo (NSV). The trials showed significant improvements in skin repigmentation, leading Pfizer to prepare global regulatory submissions for the drug. LITFULO, previously approved for severe …

PFE main company
Sharemaestro market context Price above Trend Line 52 weeks +8.9% PFE stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Benzinga Earnings Main company 🇺🇸 United States

Gold Surges 3%; Bristol-Myers Squibb Earnings Top Views

U.S. stocks saw broad gains, with the Dow up 0.40%, NASDAQ surging 2.08%, and the S&P 500 rising 0.89%. Bristol-Myers Squibb reported better-than-expected Q2 earnings and raised its FY2026 guidance, while gold prices surged 3%. Several companies, including Columbus McKinnon, Marketaxess Holdings, and Xerox …

BMY main company
Sharemaestro market context Trend signal active 52 weeks +38.1% BMY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Fierce Pharma Earnings Provider-linked mention 🇺🇸 United States

Booming Dupixent sales fuel Regeneron's biggest quarter since pandemic

Regeneron's Q2 saw its largest quarterly revenue increase since the pandemic, primarily driven by booming Dupixent sales which reached $6 billion globally. This growth, fueled by label expansions including a key COPD approval, led to a 38% year-over-year increase for Dupixent. Regeneron also reported …

SNY mentioned
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1% SNY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Grifols (GRFS) reshapes board, Audit and Strategy Committees

Grifols S.A. has announced significant changes to its Board of Directors and key committees. Mr. Iñigo Sánchez-Asiaín Mardones resigned for professional reasons, leading to the appointment of Ms. Joanna Susan Le Couilliard as a new independent director and Chairperson of the Audit Committee. Additionally, …

GRFS main company
Sharemaestro market context Price below Trend Line 52 weeks -23.4% GRFS stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Eli Lilly and Co Stock (LLY) Moved Down by 4.09% on Jul 30: Key Drivers Unveiled

Eli Lilly and Co (LLY) stock experienced a 4.09% decline on July 30, driven by profit-taking, increasing competitive pressure in the weight-loss market from rival GLP-1 candidates, and regulatory concerns over Medicare price negotiations impacting large-cap pharmaceutical stocks. Technical factors like broken moving averages …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3% LLY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quiver Quantitative Earnings Main company 🇺🇸 United States

Johnson & Johnson Falls as Investors Reassess Talc Settlement Costs After Initial Relief Rally

Johnson & Johnson's stock fell 4.0% today, likely due to investors reassessing the financial implications of its proposed $5.5 billion talc settlement. While the agreement aims to resolve many U.S. ovarian talc claims, the market is now focusing on the significant cash commitment and …

JNJ main company
Sharemaestro market context Trend signal active 52 weeks +48.8% JNJ stored weekly price path from 22 Aug 2025 to 14 Aug 2026
AllSci Earnings Main company 🇺🇸 United States

Biogen accelerates lupus and rejection trials to H1 2027 as lecanemab subcutaneous reshapes Alzheimer's access

Biogen's Q2 2026 earnings call highlighted five upcoming registrational readouts for lupus, antibody-mediated rejection, and Dravet syndrome, with a significant announcement being the FDA approval of a subcutaneous lecanemab formulation for Alzheimer's. The company accelerated trials for lupus and antibody-mediated rejection to H1 2027, …

BIIB main company
Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3% BIIB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Fierce Pharma Earnings Main company 🇺🇸 United States

Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat

Bristol Myers Squibb has once again delayed the phase 3 data readout for its Alzheimer's disease psychosis drug, Cobenfy, moving the expected arrival of data to early 2027 due to slower patient enrollment and relapse event accrual. Despite this setback and a muted launch …

BMY main company
Sharemaestro market context Trend signal active 52 weeks +38.1% BMY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MedTech Dive Market update Main company 🇺🇸 United States

What J&J’s Ottava robot brings to the surgical table

Johnson & Johnson's Ottava surgical robot recently received FDA de novo authorization, positioning it as a distinct competitor in the robotic surgery market. Unlike cart-based systems, Ottava integrates four robotic arms into the operating table, making it 30-50% smaller and enabling its use in …

JNJ main company
Sharemaestro market context Trend signal active 52 weeks +48.8% JNJ stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Pluang Market update Main company 🇺🇸 United States

MIRA Pharmaceuticals advances non-opioid pain and obesity drug candidates toward IND-enabling studies.

MIRA Pharmaceuticals has successfully advanced its two primary drug candidates, MIRA-55 for chronic inflammatory pain and SKNY-1 for obesity and addiction disorders, through key preclinical development phases. These stages included optimizing formulation, manufacturing, and conducting exploratory toxicology studies. The company is now preparing to …

MIRA main company
Sharemaestro market context Price below Trend Line 52 weeks -45.4% MIRA stored weekly price path from 22 Aug 2025 to 14 Aug 2026
pharmaphorum Earnings Main company 🇺🇸 United States

Sanofi drops two more programmes in R&D clear-out

Sanofi is discontinuing the development of two more R&D programs, anti-IL33 antibody itepekimab and TNF inhibitor balinatunfib, as part of a significant R&D clear-out under new CEO Belén Garijo. This follows the recent termination of amlitelimab for atopic dermatitis, marking a substantial shift in …

SNY main company
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1% SNY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Seeking Alpha Deals and strategy Main company 🇺🇸 United States

J&J wins FDA priority review for Rybrevant Faspro (JNJ:NYSE)

Johnson & Johnson (JNJ) has received a priority review from the FDA for its cancer therapy, Rybrevant Faspro, in partnership with Halozyme (HALO). This review is aimed at expanding the drug's label for use in treating a specific type of head and neck cancer. …

JNJ main company
Sharemaestro market context Trend signal active 52 weeks +48.8% JNJ stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Reuters Deals and strategy Main company 🇺🇸 United States

Lilly, Resilience to invest $750 million in US drug manufacturing expansion

Eli Lilly and contract manufacturer Resilience are investing $750 million to expand pharmaceutical manufacturing capacity in the U.S. and bolster the domestic medicine supply chain. This investment will create 400 new jobs in Cincinnati, Ohio, and include the production of Lilly's KwikPen injectable device. …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3% LLY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Benzinga Earnings Main company 🇺🇸 United States

Jim Cramer: Eli Lilly Is A 'Good Company,' But Doesn't 'Really Care For' This Quantum Stock

Jim Cramer expressed his positive view on Eli Lilly (NYSE: LLY), calling it a "good company" he intends to hold for years due to its strong business and drugs. However, he stated he doesn't "really care for" Rigetti Computing, Inc (NASDAQ: RGTI), despite its …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3% LLY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Fierce Pharma Deals and strategy Main company 🇺🇸 United States

Lilly, Resilience commit $750M to boost US diabetes, obesity med production

Eli Lilly and CDMO Resilience are investing $750 million to expand production of Lilly's KwikPen injectable device, used for its diabetes and obesity medications like Mounjaro and Zepbound. This investment will upgrade Resilience's Ohio facility, creating 400 new jobs and aiming for full KwikPen …

LLY main company
Sharemaestro market context Trend signal active 52 weeks +66.6% · Next-week setup positive 58.3% LLY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Earnings Main company 🇺🇸 United States

Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?

This article analyzes Gilead Sciences (GILD) to determine if it's a worthwhile investment, given its recent appearance on Zacks.com's most-searched stocks list. It examines fundamental factors such as earnings estimate revisions, projected revenue growth, and valuation, highlighting the stock's recent performance and current Zacks …

GILD main company
Sharemaestro market context Price above Trend Line 52 weeks +23.7% GILD stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartz Earnings Main company 🇺🇸 United States

Bristol Myers Squibb raises 2026 forecast after Q2 earnings beat

Bristol Myers Squibb has increased its full-year revenue and earnings forecast for 2026 following better-than-expected second-quarter results. Strong sales of its blood thinner Eliquis, along with newer drugs like Camzyos and Reblozyl, drove revenue to $12.97 billion, surpassing analyst estimates. The company now expects …

BMY main company
Sharemaestro market context Trend signal active 52 weeks +38.1% BMY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Earnings Main company 🇺🇸 United States

Canaccord raises Biogen stock price target to $248 on strong quarter

Canaccord Genuity increased its price target for Biogen Inc. (NASDAQ:BIIB) to $248 from $245, maintaining a Buy rating after the company's strong second-quarter results. Biogen surpassed revenue and EPS estimates with $2.74 billion and $3.60, respectively, driven by solid performance in its multiple sclerosis …

BIIB main company
Sharemaestro market context Trend signal active 52 weeks +50.6% · Next-week setup positive 55.3% BIIB stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MarketBeat Earnings Main company 🇺🇸 United States

Merck & Co., Inc. Plans Quarterly Dividend of $0.85 (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) has declared a quarterly dividend of $0.85 per share, payable on October 7th to shareholders of record on September 15th. This represents an annualized dividend of $3.40 and a 2.6% yield. The company has a strong dividend history, having …

MRK main company
Sharemaestro market context Trend signal active 52 weeks +60.7% MRK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Manila Times Market update Main company 🇺🇸 United States

MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies

MIRA Pharmaceuticals announced significant progress in the development of its two lead preclinical programs, MIRA-55 for chronic inflammatory pain and SKNY-1 for obesity and addiction-related disorders. The company has completed 7-day toxicology and pharmacokinetic studies, alongside formulation optimization, CMC activities, and manufacturing development. These …

MIRA main company
Sharemaestro market context Price below Trend Line 52 weeks -45.4% MIRA stored weekly price path from 22 Aug 2025 to 14 Aug 2026
BioSpace Deals and strategy Main company 🇺🇸 United States

Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions

Sanofi's new CEO, Belén Garijo, is implementing a more rigorous approach to pipeline prioritization and Phase 3 go/no-go decisions, focusing on assets with strong scientific merit and long-term value. This strategy follows the discontinuation of several programs, including most amlitelimab trials, and aims to …

SNY main company
Sharemaestro market context Price below Trend Line 52 weeks -10.1% · Next-week setup positive 56.1% SNY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

MIRA's Two Oral Drug Candidates Finish Dosing in Rats and Dogs

MIRA Pharmaceuticals announced that its two lead preclinical programs, MIRA-55 (for chronic inflammatory pain) and SKNY-1 (for obesity and addiction-related disorders), have completed the dosing phase of exploratory 7-day toxicology studies in rats and dogs. This advancement, alongside formulation optimization and manufacturing activities, moves …

MIRA main company
Sharemaestro market context Price below Trend Line 52 weeks -45.4% MIRA stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Earnings Main company 🇺🇸 United States

MIRA Pharmaceuticals completes toxicology studies for two candidates

MIRA Pharmaceuticals (NASDAQ:MIRA) announced the completion of 7-day toxicology and pharmacokinetic studies for its two preclinical drug candidates, MIRA-55 and SKNY-1. MIRA-55 is being developed for chronic inflammatory pain, while SKNY-1 is for obesity and addiction-related disorders. The company is advancing both programs through …

MIRA main company
Sharemaestro market context Price below Trend Line 52 weeks -45.4% MIRA stored weekly price path from 22 Aug 2025 to 14 Aug 2026
BioSpace Earnings Main company 🇺🇸 United States

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026

Bristol Myers Squibb reported its second-quarter 2026 financial results, which can be viewed on the company's Investor Relations website. The biopharmaceutical company hosted a conference call and live audio webcast for analysts and investors to discuss these results. A replay of the webcast will …

BMY main company
Sharemaestro market context Trend signal active 52 weeks +38.1% BMY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

JUVÉDERM marks 20 years since FDA approval with buy-one-get-one $75 cards

AbbVie's Allergan Aesthetics announced the fourth annual JUVÉDERM® Day will occur on August 19, 2026, coinciding with the 20th anniversary of the brand's first U.S. FDA dermal filler approval. Allē members can access a buy-one-get-one $75 JUVÉDERM® gift card promotion and double Allē points …

ABBV main company
Sharemaestro market context Trend signal active 52 weeks +21.3% · Next-week setup positive 57.6% ABBV stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context